发明名称 |
Therapeutic uses of BR43X2 soluble receptors |
摘要 |
<p>There is provided a fusion protein consisting of a first portion and a second portion joined by a peptide bond, wherein said first portion consists of an amino acid sequence selected from: (i) amino acid residues 25-104 of SEQ ID NO: 6; (ii) amino acid residues 34-66 of SEQ ID NO: 6; (iii) amino acid residues 71-104 of SEQ ID NO: 6; and (iv) amino acid residues 34-66 and 71-104 of SEQ ID NO: 6; and said second portion is an immunoglobulin heavy chain constant region. There is also provided an antibody or antibody fragment that specifically binds to a polypeptide selected from SEQ ID NO: 59 or SEQ ID N: 60. There is also provided an antibody or antibody fragment that specifically binds to a ztnf4 polypeptide, for use in treating systemic lupus erythematosus in a mammal.</p> |
申请公布号 |
EP2256199(A1) |
申请公布日期 |
2010.12.01 |
申请号 |
EP20100175468 |
申请日期 |
2000.01.07 |
申请人 |
ZYMOGENETICS, INC. |
发明人 |
GROSS, JANE A.;XU, WENFENG;MADDEN, KAREN L.;YEE, DAVID P. |
分类号 |
C12N15/09;C12N15/11;A61K38/00;A61K38/17;A61K39/395;A61P3/10;A61P7/02;A61P7/06;A61P9/12;A61P11/00;A61P11/06;A61P13/12;A61P19/02;A61P21/04;A61P25/28;A61P29/00;A61P31/04;A61P31/18;A61P35/00;A61P35/02;A61P37/00;A61P37/02;A61P37/06;A61P43/00;C07K14/705;C07K14/715;C07K16/28;C07K19/00;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12P21/02;C12P21/08 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|